Literature DB >> 782808

[Sisomicin versus gentamicin. A comparison of antibacterial and pharmacokinetic properties (author's transl)].

P Naumann, H Rosin, E Reintjens, M Köhler.   

Abstract

In a comparison of the antibacterial in-vitro activity of sisomicin, gentamicin, and tobramycine, sisomicin showed a higher activity against E. coli, indole-positive Proteus spp. and organisms of the Klebsiella-Enterobacter-Serratia group, whereas tobramycine was superior against Pseudomonas spp. However, the differences in activity between sisomicin and gentamicin were only within one step of dilution which is hardly sufficient to guarantee a basic superiority of one or the other preparation for clinical purposes. In 12 healthy probands serum levels and renal elimination of sisomicin and gentamicin after a single intramuscular injection of 1 mg/kg body weight were investigated in a randomised change-over trial. With corresponding serum levels, almost identical elimination half-lives of 109 and 111 minutes, and recovery values of 84 and 88.4%, respectively, there were no significant differences in the pharmacokinetics of sisomicin and gentamicin. Thus in the antibacterial treatment of gentamicin-sensitive gram-negative organisms sisomicin presents an equally good alternative. With organisms only moderately sensitive or resistant to gentamicin, sisomicin, tobramycine and amikacin should be additionally tested.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 782808     DOI: 10.1055/s-0028-1104256

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  2 in total

1.  [Experience with sisomicin in pediatrics (author's transl)].

Authors:  L Weingärtner; U Sitka; R Patsch; U Burchardt; I Richter
Journal:  Infection       Date:  1979       Impact factor: 3.553

2.  [Pharmacokinetic and clinical studies with sisomicin in paediatrics (author's transl)].

Authors:  M Doerck; G Fricke; G Gruenwaldt; H M von Hattingberg; M Scheer
Journal:  Infection       Date:  1980       Impact factor: 3.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.